Tech Transfer: Lilly, Purdue University Work To Optimize Injectable Therapies
Five-year collaboration between the Indiana-based pharma and university also hopes to develop predictive modeling for clinical development success.
You may also be interested in...
Lilly, Nektar Partner On 'Stimulating' IL-2 Drug In Autoimmune Diseases
Nektar taps into Lilly's immunology know-how for fast development of NKTR-358, which targets IL-2 to stimulate the body's own inflammation-inhibiting Tregs rather than suppress the immune system.
Cidara’s Novel Antifungal Approved For Antimicrobial-Resistant C. Auris Infections
Cidara’s US commercial partner Melinta will launch the novel echinocandin this summer, announcing pricing shortly before rollout. Limited indication follows recommendation of FDA advisory panel.
89bio’s Phase IIb Data Heighten Competition Within NASH FGF21 Analog Class
89bio’s pegozafermin met co-primary endpoints of fibrosis reduction and NASH resolution in Phase IIb; the company said its methodology yielded lower placebo responses than in Akero’s Phase IIb study.